Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Couriel

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Blood|April 8, 2004
Tumor necrosis factor-alpha blockade for the treatment of acute GVHDDaniel Couriel, Rima Saliba, Krystal Hicks, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|February 13, 2026
The actual usefulness of culturing apheresis products in hematopoietic stem cell autotransplantsMichelle Lavoignet-Cisneros, Lidia Joanna Alberto-López, Miguel Ángel Viveros-Lugo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2016
Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host DiseaseHolly K Miller, Thomas M Braun, Terri Stillwell, et al.
Blood|November 18, 2006
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host diseaseMargaret L Macmillan, Daniel Couriel, Daniel J Weisdorf, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2007
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalanBetul Oran, Sergio Giralt, Rima Saliba, et al.
Frontiers in Immunology|February 5, 2026
Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024Gisela Maria Suárez Formigo, Zaima Mazorra, Cinthia Olexen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 26, 2006
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group reportPaul J Martin, Daniel Weisdorf, Donna Przepiorka, et al.
Bone Marrow Transplantation|July 21, 2015
FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AMLYeohan Song, John Magenau, Yumeng Li, et al.
Haematologica|January 29, 2008
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experiencePaolo Anderlini, Rima Saliba, Sandra Acholonu, et al.
Blood|June 6, 2012
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaAndrzej J Jakubowiak, Dominik Dytfeld, Kent A Griffith, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Blood|April 8, 2004
Tumor necrosis factor-alpha blockade for the treatment of acute GVHDDaniel Couriel, Rima Saliba, Krystal Hicks, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|February 13, 2026
The actual usefulness of culturing apheresis products in hematopoietic stem cell autotransplantsMichelle Lavoignet-Cisneros, Lidia Joanna Alberto-López, Miguel Ángel Viveros-Lugo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2016
Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host DiseaseHolly K Miller, Thomas M Braun, Terri Stillwell, et al.
Blood|November 18, 2006
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host diseaseMargaret L Macmillan, Daniel Couriel, Daniel J Weisdorf, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2007
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalanBetul Oran, Sergio Giralt, Rima Saliba, et al.
Frontiers in Immunology|February 5, 2026
Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024Gisela Maria Suárez Formigo, Zaima Mazorra, Cinthia Olexen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 26, 2006
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group reportPaul J Martin, Daniel Weisdorf, Donna Przepiorka, et al.
Bone Marrow Transplantation|July 21, 2015
FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AMLYeohan Song, John Magenau, Yumeng Li, et al.
Haematologica|January 29, 2008
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experiencePaolo Anderlini, Rima Saliba, Sandra Acholonu, et al.
Blood|June 6, 2012
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaAndrzej J Jakubowiak, Dominik Dytfeld, Kent A Griffith, et al.
Pageof 8